Evidence map›Paper›PMID 32328653›Full record

ReviewNeuro-oncology2020

Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

Patrick Y Wen, Michael Weller, Eudocia Quant Lee, Brian M Alexander, Jill S Barnholtz-Sloan, Floris P Barthel, Tracy T Batchelor, Ranjit S Bindra, Susan M Chang, E Antonio Chiocca and 30 more

Abstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 792 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
792citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

792 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. NAR cancer · 2026
    Article
  15. Observational
  16. Article
  17. Review
  18. Article
  19. Accelerating discovery: Transformative clinical trial models in neuro-oncology.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  20. Review

732 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

40 authors.

Patrick Y WenDana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Michael WellerDepartment of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
Eudocia Quant LeeDana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Brian M AlexanderDana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Jill S Barnholtz-SloanCase Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio, USA.
Floris P BarthelThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA.
Tracy T BatchelorDepartment of Neurology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School.
Ranjit S BindraDepartment of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut, USA.
Susan M ChangUniversity of California San Francisco, San Francisco, California, USA.
E Antonio ChioccaDepartment of Neurosurgery, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.
Timothy F CloughesyDavid Geffen School of Medicine, Department of Neurology, University of California Los Angeles, Los Angeles, California, USA.
John F DeGrootDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Evanthia GalanisMayo Clinic, Rochester, Minnesota, USA.
Mark R GilbertNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Monika E HegiLausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Craig HorbinskiDepartment of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Raymond Y HuangDivision of Neuroradiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Andrew B LassmanDepartment of Neurology and Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA.
Emilie Le RhunUniversity of Lille, Inserm, Neuro-oncology, General and Stereotaxic Neurosurgery service, University Hospital of Lille, Lille, France; Breast Cancer Department, Oscar Lambret Center, Lille, France and Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
Michael LimDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Minesh P MehtaMiami Cancer Institute, Miami, Florida, USA.
Ingo K MellinghoffDepartment of Neurology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Giuseppe MinnitiRadiation Oncology Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
David NathansonDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California, USA.
Michael PlattenDepartment of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany.
Matthias PreusserDivision of Oncology, Department of Medicine, Medical University of Vienna, Vienna, Austria.
Patrick RothDepartment of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
Marc SansonSorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.
David SchiffUniversity of Virginia School of Medicine, Division of Neuro-Oncology, Department of Neurology, University of Virginia, Charlottesville, Virginia, USA.
Susan C ShortLeeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.
Martin J B TaphoornDepartment of Neurology, Medical Center Haaglanden, The Hague and Department of Neurology, Leiden University Medical Center, the Netherlands.
Joerg-Christian TonnDepartment of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.
Jonathan TsangDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California, USA.
Roel G W VerhaakThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA.
Andreas von DeimlingNeuropathology and Clinical Cooperation Unit Neuropathology, University Heidelberg and German Cancer Center, Heidelberg, Germany.
Wolfgang WickDepartment of Neurology and Neuro-oncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Gelareh ZadehMacFeeters Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Centre, Toronto, Canada.
David A ReardonDana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Kenneth D AldapeLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Martin J van den BentDepartment of Neurology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
The role of microvesicles in giloma virotherapyP01CA069246 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHIOCCA, E. ANTONIO · 1996 to 2021
$30.9M
The Tumor Microenvironmental Barrier to Effective Viral OncolysisP01CA163205 · NCI · OHIO STATE UNIVERSITY · PI KEITH LLOYD LIGON · 2013 to 2026
$26.0M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Brain Tumor Clinical and Clinical Research Program (Clinical Support Services)ZIDBC011642 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI OZER, BYRAM · 2015 to 2025
$23.4M
Molecular Mechanisms of Drug Resistance in Primary Brain TumorsR35NS105109 · NINDS · SLOAN-KETTERING INST CAN RESEARCH · PI MELLINGHOFF, INGO K · 2018 to 2025
$4.7M
Rare Central Nervous System Cancers InitiativeZIABC011643 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GILBERT, MARK · 2015 to 2024
$4.2M
Identifying New Glioma-Associated Tumor Suppressors OncogenesZIABC011647 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GILBERT, MARK · 2015 to 2024
$4.2M
Translational ImmunologyZIABC011714 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GILBERT, MARK · 2016 to 2024
$4.0M
Exploring the Therapeutic Potential of Stem Cell Biology in GliomasZIABC011640 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GILBERT, MARK · 2015 to 2024
$3.1M
NCATS NIH HHS UL1 TR001863NCI NIH HHS P01 CA069246NCI NIH HHS P01 CA163205NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA211015NINDS NIH HHS R35 NS105109
6 · The paper itself

Abstract

Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. In addition, novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, and viral therapies will be reviewed, as well as the current challenges and future directions for research.

Indexed as

Brain NeoplasmsGlioblastomaChemoradiotherapyClinical Trials, Phase III as TopicHumansIsocitrate DehydrogenaseRandomized Controlled Trials as TopicIsocitrate Dehydrogenaseclinical trialsdiagnosisglioblastomatherapy

Identifiers

PMID32328653
PMCPMC7594557

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.